Skip to main content

What is LEUKOTAC®?

What is LEUKOTAC®?

LEUKOTAC® (inolimomab) is an immunotherapy monoclonal antibody that targets the interleukin-2 receptor (IL-2), a chemical molecule named cytokine that contributes to the development and proliferation of some white blood cells including T-cells responsible for aGvHD. By linking specifically to the α chain of the receptor (CD25), LEUKOTAC® prevents IL-2 from binding on the surface of the donor’s over-active T-cells which blocks their multiplication.

The efficacy of LEUKOTAC® in steroid-resistant aGvHD lies mainly in its specificity and its preferential affinity to the CD25 receptor found on the surface of T-lymphocytes.

Mode of action of LEUKOTAC®

Latest news on Leukotac

Discover our latest news regarding our pipeline, our partnerships and more

Thu, 04/05/2018 - 09:00
  • ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to c

Thu, 03/15/2018 - 17:00
  • A poster summarising the safety profile results of the randomised Phase 3 testing LEUKOTAC® in patients with steroid-resistant acute gra

Thu, 10/12/2017 - 17:00
  • In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® i

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter